Therefore, pharmacologic modulation of the NO–sGC–cGMP pathway was one of the first therapeutic strategies in pulmonary hypertension (PH) with phosphodiesterase type 5 inhibitors (PDE5is) (sildenafil and tadalafil), which prevent degradation of cGMP, approved as treatment for patients with pulmonary arterial hypertension (PAH) [3–6]. Here, SGCB is linked to pulmonary arterial hypertension.